Utilization, Cost Trends, and Member Cost - Share for Self-Injectable Multiple Sclerosis Drugs-Pharmacy and Medical Benefit Spending From 2004 Through 2007

BACKGROUND: In 1993, interferon beta-1b became the first of 4 self-injectable multiple sclerosis (MS) drugs to be approved by the U.S. Food and Drug Administration. Initially covered as a medical expense, self-inject able MS drugs are increasingly considered specialty pharmaceuticals and are often c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunze, April M., Gunderson, Brent W., Gleason, Patrick P., Heaton, Alan H., Johnson, Steven V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2007
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437890/
https://www.ncbi.nlm.nih.gov/pubmed/18062731
http://dx.doi.org/10.18553/jmcp.2007.13.9.799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437890/
https://www.ncbi.nlm.nih.gov/pubmed/18062731
http://dx.doi.org/10.18553/jmcp.2007.13.9.799

Ejemplares similares